Copyright Reports & Markets. All rights reserved.

Global Entyvio (vedolizumab) Drug Market Report 2018-2029

Request for Sample of this report
Buy now

1 Industry Overview of Entyvio (vedolizumab) Drug

  • 1.1 Research Scope
  • 1.2 Market Segmentation by Types of Entyvio (vedolizumab) Drug
  • 1.3 Market Segmentation by End Users of Entyvio (vedolizumab) Drug
  • 1.4 Market Dynamics Analysis of Entyvio (vedolizumab) Drug
    • 1.4.1 Market Drivers
    • 1.4.2 Market Challenges
    • 1.4.3 Market Opportunities
    • 1.4.4 Porter’s Five Forces

2 Major Manufacturers Analysis of Entyvio (vedolizumab) Drug Industry

  • 2.1 Takeda
    • 2.1.1 Company Overview
    • 2.1.2 Main Products and Specifications
    • 2.1.3 Entyvio (vedolizumab) Drug Sales Volume, Revenue, Price and Gross Margin (2018-2023)
    • 2.1.4 Contact Information

3 Global Entyvio (vedolizumab) Drug Market Analysis by Regions, Manufacturers, Types and End Users

  • 3.1 Global Sales Volume and Revenue of Entyvio (vedolizumab) Drug by Regions (2018-2023)
  • 3.2 Global Sales Volume and Revenue of Entyvio (vedolizumab) Drug by Manufacturers (2018-2023)
  • 3.3 Global Sales Volume and Revenue of Entyvio (vedolizumab) Drug by Types (2018-2023)
  • 3.4 Global Sales Volume and Revenue of Entyvio (vedolizumab) Drug by End Users (2018-2023)
  • 3.5 Selling Price Analysis of Entyvio (vedolizumab) Drug by Regions, Manufacturers, Types and End Users in (2018-2023)

4 Northern America Entyvio (vedolizumab) Drug Market Analysis by Countries, Types and End Users

  • 4.1 Northern America Entyvio (vedolizumab) Drug Sales Volume and Revenue Analysis by Countries (2018-2023)
  • 4.2 Northern America Entyvio (vedolizumab) Drug Sales Volume and Revenue Analysis by Types (2018-2023)
  • 4.3 Northern America Entyvio (vedolizumab) Drug Sales Volume and Revenue Analysis by End Users (2018-2023)
  • 4.4 United States Entyvio (vedolizumab) Drug Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 4.5 Canada Entyvio (vedolizumab) Drug Sales Volume, Revenue, Import and Export Analysis (2018-2023)

5 Europe Entyvio (vedolizumab) Drug Market Analysis by Countries, Types and End Users

  • 5.1 Europe Entyvio (vedolizumab) Drug Sales Volume and Revenue Analysis by Countries (2018-2023)
  • 5.2 Europe Entyvio (vedolizumab) Drug Sales Volume and Revenue Analysis by Types (2018-2023)
  • 5.3 Europe Entyvio (vedolizumab) Drug Sales Volume and Revenue Analysis by End Users (2018-2023)
  • 5.4 Germany Entyvio (vedolizumab) Drug Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 5.5 France Entyvio (vedolizumab) Drug Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 5.6 UK Entyvio (vedolizumab) Drug Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 5.7 Italy Entyvio (vedolizumab) Drug Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 5.8 Russia Entyvio (vedolizumab) Drug Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 5.9 Spain Entyvio (vedolizumab) Drug Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 5.10 Netherlands Entyvio (vedolizumab) Drug Sales Volume, Revenue, Import and Export Analysis (2018-2023)

6 Asia Pacific Entyvio (vedolizumab) Drug Market Analysis by Countries, Types and End Users

  • 6.1 Asia Pacific Entyvio (vedolizumab) Drug Sales Volume and Revenue Analysis by Countries (2018-2023)
  • 6.2 Asia Pacific Entyvio (vedolizumab) Drug Sales Volume and Revenue Analysis by Types (2018-2023)
  • 6.3 Asia Pacific Entyvio (vedolizumab) Drug Sales Volume and Revenue Analysis by End Users (2018-2023)
  • 6.4 China Entyvio (vedolizumab) Drug Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 6.5 Japan Entyvio (vedolizumab) Drug Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 6.6 Korea Entyvio (vedolizumab) Drug Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 6.7 India Entyvio (vedolizumab) Drug Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 6.8 Australia Entyvio (vedolizumab) Drug Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 6.9 Indonesia Entyvio (vedolizumab) Drug Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 6.10 Vietnam Entyvio (vedolizumab) Drug Sales Volume, Revenue, Import and Export Analysis (2018-2023)

7 Latin America Entyvio (vedolizumab) Drug Market Analysis by Countries, Types and End Users

  • 7.1 Latin America Entyvio (vedolizumab) Drug Sales Volume and Revenue Analysis by Countries (2018-2023)
  • 7.2 Latin America Entyvio (vedolizumab) Drug Sales Volume and Revenue Analysis by Types (2018-2023)
  • 7.3 Latin America Entyvio (vedolizumab) Drug Sales Volume and Revenue Analysis by End Users (2018-2023)
  • 7.4 Brazil Entyvio (vedolizumab) Drug Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 7.5 Mexico Entyvio (vedolizumab) Drug Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 7.6 Argentina Entyvio (vedolizumab) Drug Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 7.7 Colombia Entyvio (vedolizumab) Drug Sales Volume, Revenue, Import and Export Analysis (2018-2023)

8 Middle East & Africa Entyvio (vedolizumab) Drug Market Analysis by Countries, Types and End Users

  • 8.1 Middle East & Africa Entyvio (vedolizumab) Drug Sales Volume and Revenue Analysis by Countries (2018-2023)
  • 8.2 Middle East & Africa Entyvio (vedolizumab) Drug Sales Volume and Revenue Analysis by Types (2018-2023)
  • 8.3 Middle East & Africa Entyvio (vedolizumab) Drug Sales Volume and Revenue Analysis by End Users (2018-2023)
  • 8.4 Turkey Entyvio (vedolizumab) Drug Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 8.5 Saudi Arabia Entyvio (vedolizumab) Drug Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 8.6 South Africa Entyvio (vedolizumab) Drug Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 8.7 Egypt Entyvio (vedolizumab) Drug Sales Volume, Revenue, Import and Export Analysis (2018-2023)

9 Marketing Channel, Distributors and Traders Analysis

  • 9.1 Marketing Channel
    • 9.1.1 Direct Channel
    • 9.1.2 Indirect Channel
  • 9.2 Distributors and Traders

10 Global Entyvio (vedolizumab) Drug Market Forecast by Regions, Countries, Manufacturers, Types and End Users

  • 10.1 Global Sales Volume and Revenue Forecast of Entyvio (vedolizumab) Drug by Regions (2024-2029)
  • 10.2 Global Sales Volume and Revenue Forecast of Entyvio (vedolizumab) Drug by Types (2024-2029)
  • 10.3 Global Sales Volume and Revenue Forecast of Entyvio (vedolizumab) Drug by End Users (2024-2029)
  • 10.4 Global Revenue Forecast of Entyvio (vedolizumab) Drug by Countries (2024-2029)
    • 10.4.1 United States Revenue Forecast (2024-2029)
    • 10.4.2 Canada Revenue Forecast (2024-2029)
    • 10.4.3 Germany Revenue Forecast (2024-2029)
    • 10.4.4 France Revenue Forecast (2024-2029)
    • 10.4.5 UK Revenue Forecast (2024-2029)
    • 10.4.6 Italy Revenue Forecast (2024-2029)
    • 10.4.7 Russia Revenue Forecast (2024-2029)
    • 10.4.8 Spain Revenue Forecast (2024-2029)
    • 10.4.9 Netherlands Revenue Forecast (2024-2029)
    • 10.4.10 China Revenue Forecast (2024-2029)
    • 10.4.11 Japan Revenue Forecast (2024-2029)
    • 10.4.12 Korea Revenue Forecast (2024-2029)
    • 10.4.13 India Revenue Forecast (2024-2029)
    • 10.4.14 Australia Revenue Forecast (2024-2029)
    • 10.4.15 Indonesia Revenue Forecast (2024-2029)
    • 10.4.16 Vietnam Revenue Forecast (2024-2029)
    • 10.4.17 Brazil Revenue Forecast (2024-2029)
    • 10.4.18 Mexico Revenue Forecast (2024-2029)
    • 10.4.19 Argentina Revenue Forecast (2024-2029)
    • 10.4.20 Colombia Revenue Forecast (2024-2029)
    • 10.4.21 Turkey Revenue Forecast (2024-2029)
    • 10.4.22 Saudi Arabia Revenue Forecast (2024-2029)
    • 10.4.23 South Africa Revenue Forecast (2024-2029)
    • 10.4.24 Egypt Revenue Forecast (2024-2029)

11 Industry Chain Analysis of Entyvio (vedolizumab) Drug

  • 11.1 Upstream Major Raw Materials and Equipment Suppliers Analysis of Entyvio (vedolizumab) Drug
    • 11.1.1 Major Raw Materials Suppliers with Contact Information Analysis of Entyvio (vedolizumab) Drug
    • 11.1.2 Major Equipment Suppliers with Contact Information Analysis of Entyvio (vedolizumab) Drug
  • 11.2 Downstream Major Consumers Analysis of Entyvio (vedolizumab) Drug
  • 11.3 Major Suppliers of Entyvio (vedolizumab) Drug with Contact Information
  • 11.4 Supply Chain Relationship Analysis of Entyvio (vedolizumab) Drug

12 Entyvio (vedolizumab) Drug New Project Investment Feasibility Analysis

  • 12.1 Entyvio (vedolizumab) Drug New Project SWOT Analysis
  • 12.2 Entyvio (vedolizumab) Drug New Project Investment Feasibility Analysis
    • 12.2.1 Project Name
    • 12.2.2 Investment Budget
    • 12.2.3 Project Product Solutions
    • 12.2.4 Project Schedule

13 Entyvio (vedolizumab) Drug Research Findings and Conclusion

    14 Appendix

    • 14.1 Research Methodology
    • 14.2 References and Data Sources
      • 14.2.1 Primary Sources
      • 14.2.2 Secondary Paid Sources
      • 14.2.3 Secondary Public Sources
    • 14.3 Abbreviations and Units of Measurement
    • 14.4 Author Details

    Entyvio (vedolizumab) is a prescription drug used to treat inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. The drug works by targeting the inflammation in the gut, where it selectively blocks white blood cells from infiltrating and causing further damage. The global Entyvio (vedolizumab) drug market size in 2022 is projected to be US$6449 million, with a compound annual growth rate of 26%. This article will provide an analysis of the Entyvio (vedolizumab) drug industry, including its definition, use, industry status, and prospects.

    Entyvio (vedolizumab) is a monoclonal antibody drug that selectively targets and blocks the gut-specific lymphocyte trafficking alpha-4 beta-7 integrin protein. The drug reduces inflammation in the gut and the associated symptoms of ulcerative colitis and Crohn's disease, such as abdominal pain, diarrhea, and rectal bleeding. Entyvio (vedolizumab) is administered through an IV infusion once every eight weeks.

    The global Entyvio (vedolizumab) drug market is expected to experience robust growth in the coming years. The increasing incidence of inflammatory bowel diseases globally, growing awareness about the availability of effective treatment options, and rising investments in healthcare are the primary factors driving the growth of the Entyvio (vedolizumab) drug market.

    Takeda dominates the global market share for Entyvio (vedolizumab) drug, with a significant market presence in the United States, Europe, and Japan. The company has invested significantly in research and development to develop innovative treatments to address unmet medical needs.

    The Entyvio (vedolizumab) drug industry is projected to experience strong growth in the coming years. The global market size is expected to reach US$6449 million in 2022, with a compound annual growth rate of 26%. The demand for Entyvio (vedolizumab) drug is expected to be highest in North America and Europe, followed by the Asia Pacific region.

    Emerging markets, such as the Asia Pacific region, present significant growth potential due to increasing investments in healthcare and expanding customer bases. Moreover, the rapid development of biosimilars may pose a challenge to the industry's growth prospects.

    The Entyvio (vedolizumab) drug industry plays a crucial role in providing effective treatments to patients suffering from inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. The industry is expected to experience robust growth due to an increase in demand for effective treatments globally and rising investments in healthcare. However, the industry faces challenges such as increasing competition from biosimilars and fluctuations in raw material prices. Manufacturers need to continue investing in research and development to create more efficient and effective technologies while ensuring compliance with regulatory requirements. With the rising incidence of inflammatory bowel diseases, the Entyvio (vedolizumab) drug industry is likely to continue to experience strong growth in the coming years. Takeda's dominance in the global market creates a significant opportunity for expansion and innovation in this field.

    The SWOT analysis of the Entyvio (vedolizumab) Drug industry is as follows:

    Strengths:
    Entyvio (vedolizumab) is a highly effective drug that selectively targets and blocks the gut-specific lymphocyte trafficking alpha-4 beta-7 integrin protein, reducing inflammation in the gut and symptoms of inflammatory bowel diseases.
    Strong demand due to the increasing incidence of inflammatory bowel diseases globally, rising awareness about the availability of effective treatments and increasing investments in healthcare.
    Takeda dominates the global market share for Entyvio (vedolizumab) drug, with a significant market presence in the United States, Europe, and Japan.
    The industry is witnessing increasing research and development initiatives in novel formulations and treatment paradigms.

    Weaknesses:
    High cost of the drug may limit accessibility for some patients in certain regions, reducing overall demand.
    Competition from biosimilar drugs may pose a challenge to the industry's growth prospects.
    Limited use of Entyvio (vedolizumab) drug in other therapeutic areas may impact industry expansion potential.

    Opportunities:
    Emerging markets, particularly the Asia Pacific region, present untapped potential for growth due to the increasing investments in healthcare and expanding customer bases.
    Advancements in technology provide opportunities for manufacturers to develop more efficient and effective formulations of Entyvio (vedolizumab) drug and explore other potential therapeutic areas.
    Rising demand for biologic drugs globally present an opportunity for the industry to expand its reach.

    Threats:
    Changes in regulatory requirements and standards across different markets may pose challenges for manufacturers who must comply with different standards in different regions.
    Fluctuations in raw material prices and manufacturing costs may impact profitability for manufacturers.
    Increasing competition from alternative therapies and biosimilars may reduce the growth potential of the industry.

    Key players in global Entyvio (vedolizumab) Drug market include:
    Takeda

    Market segmentation, by product types:
    Type 1
    Type 2

    Market segmentation, by applications:
    Ulcerative Colitis
    Crohn's Disease
    Buy now